WHO EMRO - Intercountry Workshop on Monitoring Therapeutic Efficacy of Antimalarial
Prorgamme
Presentation of group work Discussion on the operational and technical issues of the WHO protocols for in vivo tests, lessons learnt from the field
Sunday, 21 April 2002 08:30 – 09:00 Registration 09:00 – 09:45 Opening Session
Dr H. El Zein, WR/Yemen
DR H. Atta 09:45 - 10:00 Coffee Break 10:00 - 10:30 Malaria in EMR –the challenge of drug resistance and regional response Dr H. Atta 10:30 - 11:00 Global overview of the status of antimalarial drug resistance and RBM response Dr P. Ringwald 11:00 -11:30 Epidemiology of drug resistance in malaria Dr A. Adeel 11:30 - 12:00 Overview of various methods used in monitoring (in vivo, in vitro, molecular, etc.) Dr P. Ringwald 12:00 - 12:30 New Antimalarials and drug Combinations
Review of Fixed Combinations Prof. Wernsdorfer 12:30-13:00 Rational use of antimalarials DR Adeel
Dr Abd Rabbo 13:00 - 14:00 Coffee break 14:00 - 15:00 Countries’ presentation on the situation of drug resistance ands monitoring activities (Group1: Sudan , Somalia, Djibouti, Blue Nile, Yemen) 15:00-15:15 Discussion and concluding remarks for group 1 15;15-15:30 Coffee break 15:30 – 16:30 Countries’ presentation on the situation of drug resistance ands monitoring activities ( Afghanistan, Iran, Pakistan, Saudi Arabia ) 16:30 – 16:45 Discussion and concluding remarks for group 2
Monday, 22 April 2002 9:00 – 9:45 In vivo methodologies: Update on WHO protocols for monitoring antimalarial therapeutic efficacy of antimalarial drugs for falciparum and (briefly) vivax malaria. Framework for monitoring in vivo data Dr R. Ringwald 9:45-10:30 Overview of the protocol for in vivo test for monitoring therapeutic efficacy of antimalarial drugs for P.falciparum Dr A Adeel 10:30 - 10:45 Coffee break 10.45 - 11.00 Discussions 11.00 – 13-00 Group work on Operational issues with the current WHO protocol (Epidemiological basis for the choice of sentinel sites, teams, training, quality control of drugs, Statistical methods in therapeutic efficacy test –sampling and analytical plan, quality control of the data, analysis of the data in different epidemiological setting) 13:00 - 14:00 Coffee break 14:00 - 16:00 Group work on Technical issues with the current WHO protocol (inclusion/exclusion criteria, classification criteria, urinary test, haemoglobin, adaptation according to transmission area or drugs) 16:00 – 16:15 Coffee break 16.15 - 17.30 Plenary session: Tuesday, 23 April 2002 9:00 – 10:00 In vitro methodologies: WHO standard in vitro test (Mark III ), analysis of in vitro data Prof. Wernsdorfer 10:00- 10:30 PCR based methods and molecular genetics Dr Ringwald 10:30-10:45 Coffee break 10.45 - 13.00 Basic Excel and Basic Epi-Info 6.04 13:00 - 14:00 Coffee break 14:00 - 15:30 Basic Excel and Basic Epi-Info 6.04 15:30 - 15:45 Coffee break 15.45 - 17.00 Analysis of the results of therapeutic efficacy test and in vitro method using Excel and Epi-Info Wednesday, 24 April 2002 09:00 - 9:30 Framework of antimalarial drug policy Dr H. Atta 9:30 – 10:00 Antimalarial drug policy change Prof. Wernsdorfer 10:00-10:30 Plenary dissuasion on the development and updating countries’ drug policy 10:30 – 10:45 Coffee break 10:45 – 13:00 Work groups for drafting the national plan for monitoring the therapeutic efficacy 13:00 - 14:00 Coffee break 14:00 – 15:30 Work group (continued) 15:30 - 15:45 Coffee break 15:45 – 17:00 Work group (continued) Thursday, 25 April 2002 09:00 – 10:30 Presentation and discussion of the draft plans 10.30 – 10:45 Coffee break 10.45 – 12:30 Conclusions and evaluation of the workshop